Liquid Biopsy and Primary Brain Tumors

Two decades of “promising results” in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Robert H. Eibl, Markus Schneemann
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	liquid biopsy brain tumor glioblastoma glioma medulloblastoma circulating tumor cell—CTC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/15b06a90d565445fb3053b7063943985
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:15b06a90d565445fb3053b7063943985
record_format	dspace
spelling	oai:doaj.org-article:15b06a90d565445fb3053b70639439852021-11-11T15:31:21ZLiquid Biopsy and Primary Brain Tumors10.3390/cancers132154292072-6694https://doaj.org/article/15b06a90d565445fb3053b70639439852021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5429https://doaj.org/toc/2072-6694Two decades of “promising results” in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA; we further discuss the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquid biopsy.Robert H. EiblMarkus SchneemannMDPI AGarticleliquid biopsybrain tumorglioblastomagliomamedulloblastomacirculating tumor cell—CTCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5429, p 5429 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liquid biopsy brain tumor glioblastoma glioma medulloblastoma circulating tumor cell—CTC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	liquid biopsy brain tumor glioblastoma glioma medulloblastoma circulating tumor cell—CTC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Robert H. Eibl Markus Schneemann Liquid Biopsy and Primary Brain Tumors
description	Two decades of “promising results” in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA; we further discuss the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquid biopsy.
format	article
author	Robert H. Eibl Markus Schneemann
author_facet	Robert H. Eibl Markus Schneemann
author_sort	Robert H. Eibl
title	Liquid Biopsy and Primary Brain Tumors
title_short	Liquid Biopsy and Primary Brain Tumors
title_full	Liquid Biopsy and Primary Brain Tumors
title_fullStr	Liquid Biopsy and Primary Brain Tumors
title_full_unstemmed	Liquid Biopsy and Primary Brain Tumors
title_sort	liquid biopsy and primary brain tumors
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/15b06a90d565445fb3053b7063943985
work_keys_str_mv	AT robertheibl liquidbiopsyandprimarybraintumors AT markusschneemann liquidbiopsyandprimarybraintumors
_version_	1718435225404440576

Liquid Biopsy and Primary Brain Tumors

Ejemplares similares